A Study of Eltrombopag and Recombinant Human Thrombopoietin In Primary Immune Thrombocytopenia

Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2020
Cargando información sobre las referencias
Thrombopoietin Receptor Agonists (TPO-ra) are novel treatments for patients with refractory Primary Immune Thrombocytopenia (ITP). Rh-TPO and eltrombopag increase the number of platelets through different mechanism. If there is cross-resistance between 2 drugs for the treatment of adult ITP is still no answer. The purpose of this study is to investigate the efficacy and safety of switching eltrombopag and Rh-TPO in adults with ITP.
Epistemonikos ID: 4fe207e24100e17ab19fe444c6437bb2103beed1
First added on: May 06, 2024